These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 16969255)

  • 1. Practical and clinical benefits of radioimmunotherapy lead to advantages in cost-effectiveness in the treatment of patients with non-Hodgkin's lymphoma.
    Otte A; Thompson SL
    Nucl Med Commun; 2006 Oct; 27(10):753-6. PubMed ID: 16969255
    [No Abstract]   [Full Text] [Related]  

  • 2. Radiolabeled immunotherapy in non-Hodgkin's lymphoma treatment: the next step.
    Otte A; van de Wiele C; Dierckx RA
    Nucl Med Commun; 2009 Jan; 30(1):5-15. PubMed ID: 19020470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosimetry and radioimmunotherapy of non-Hodgkin's lymphoma.
    Postema EJ
    J Nucl Med; 2004 Dec; 45(12):2126-7; author reply 2127. PubMed ID: 15585492
    [No Abstract]   [Full Text] [Related]  

  • 4. Radioimmunotherapy of non-Hodgkin's lymphoma revisited.
    Goldenberg DM; Sharkey RM
    J Nucl Med; 2005 Feb; 46(2):383-4. PubMed ID: 15695801
    [No Abstract]   [Full Text] [Related]  

  • 5. Radioimmunotherapy of refractory or relapsed Hodgkin's lymphoma with 90Y-labelled antiferritin antibody.
    Decaudin D; Levy R; Lokiec F; Morschhauser F; Djeridane M; Kadouche J; Pecking A
    Anticancer Drugs; 2007 Jul; 18(6):725-31. PubMed ID: 17762404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. Summary.
    Bischof Delaloye A; Conti PS; Gisselbrecht C; Gregory SA
    Oncologist; 2009; 14 Suppl 2():52-4. PubMed ID: 19819924
    [No Abstract]   [Full Text] [Related]  

  • 7. A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-131-rituximab radio-immunotherapy.
    Bishton MJ; Hicks RJ; Westerman DA; Prince MH; Wolf M; Seymour JF
    Haematologica; 2008 May; 93(5):789-90. PubMed ID: 18450737
    [No Abstract]   [Full Text] [Related]  

  • 8. Radioimmunotherapy for non-Hodgkin's lymphoma.
    Friedberg JW
    Clin Cancer Res; 2004 Dec; 10(23):7789-91. PubMed ID: 15585609
    [No Abstract]   [Full Text] [Related]  

  • 9. Radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
    Whelton S
    Nurse Pract; 2007 Dec; 32(12):35-8. PubMed ID: 18043410
    [No Abstract]   [Full Text] [Related]  

  • 10. Advances in radioimmunotherapy in the age of molecular engineering and pretargeting.
    Sharkey RM; Goldenberg DM
    Cancer Invest; 2006 Feb; 24(1):82-97. PubMed ID: 16466997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.
    Sacchi S; Marcheselli L; Bari A; Marcheselli R; Pozzi S; Luminari S; Lombardo M; Buda G; Lazzaro A; Gobbi PG; Stelitano C; Morabito F; Quarta G; Brugiatelli M
    Haematologica; 2008 Mar; 93(3):398-404. PubMed ID: 18268277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of pre-treatment radiation absorbed dose estimation for radioimmunotherapy of non-Hodgkin's lymphoma.
    Eary JF; Krohn KA; Press OW; Durack L; Bernstein ID
    Nucl Med Biol; 1997 Oct; 24(7):635-8. PubMed ID: 9352534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Will radioimmunotherapy survive?
    Zelenetz AD
    Clin Adv Hematol Oncol; 2007 Oct; 5(10):782-4. PubMed ID: 17998896
    [No Abstract]   [Full Text] [Related]  

  • 14. Defining the role of immunotherapy and radioimmunotherapy in the treatment of low-grade lymphoma.
    Winter JN
    Curr Opin Hematol; 2007 Jul; 14(4):360-8. PubMed ID: 17534162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential long-term toxicities should influence the choice of therapy for indolent non-Hodgkin's lymphoma.
    Friedberg JW
    Haematologica; 2006 Nov; 91(11):1453-5. PubMed ID: 17082005
    [No Abstract]   [Full Text] [Related]  

  • 16. Radioimmunotherapy effective first-line treatment for non-Hodgkin's lymphoma.
    Oncology (Williston Park); 2000 Jul; 14(7):1009, 1039. PubMed ID: 10929588
    [No Abstract]   [Full Text] [Related]  

  • 17. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.
    Salzburg J; Burkhardt B; Zimmermann M; Wachowski O; Woessmann W; Oschlies I; Klapper W; Wacker HH; Ludwig WD; Niggli F; Mann G; Gadner H; Riehm H; Schrappe M; Reiter A
    J Clin Oncol; 2007 Sep; 25(25):3915-22. PubMed ID: 17761975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted monoclonal antibody therapy and radioimmunotherapy for lymphoproliferative disorders of the ocular adnexa.
    Shome D; Esmaeli B
    Curr Opin Ophthalmol; 2008 Sep; 19(5):414-21. PubMed ID: 18772675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioimmunotherapy for non-Hodgkin lymphoma (NHL): nursing and patient perspectives.
    ONS News; 2004; 19(9 Suppl):49-50. PubMed ID: 15478585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma.
    Hashino S; Morioka M; Irie T; Shiroshita N; Kawamura T; Suzuki S; Iwasaki H; Umehara S; Kakinoki Y; Kurosawa M; Kahata K; Izumiyama K; Kobayashi H; Onozawa M; Takahata M; Fujisawa F; Kondo T; Asaka M
    Int J Lab Hematol; 2008 Aug; 30(4):292-9. PubMed ID: 18665826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.